Tesamorelin Dosage: FDA Label Doses for EGRIFTA WR and SV
The FDA-approved tesamorelin dose is 1.28 mg daily for EGRIFTA WR or 1.4 mg for EGRIFTA SV. See the trial dose, a dosage chart, side effects and what changed in 2025.
FDA label doses, trial doses and what research vials are not.
The FDA-approved tesamorelin dosage depends on the formulation. EGRIFTA WR, the newer version approved in March 2025, is dosed at 1.28 mg injected under the skin of the abdomen once daily. EGRIFTA SV, the version it is gradually replacing, is dosed at 1.4 mg once daily. The original EGRIFTA used in the clinical trials was dosed at 2 mg once daily. FDA labeling describes comparable systemic exposure at these formulation-specific doses, but the products are not interchangeable milligram for milligram. The approved indication for EGRIFTA WR and EGRIFTA SV is reducing excess abdominal fat in adults with HIV and lipodystrophy; the original EGRIFTA formulation is discontinued.
Key takeaways
- The approved dose is product-specific: 1.28 mg daily for EGRIFTA WR and 1.4 mg daily for EGRIFTA SV. The FDA label says the two formulations are not substitutable.
- The trials tested 2 mg daily: The two pivotal trials gave 2 mg of the original EGRIFTA formulation once a day, every day, for 26 weeks, then up to 52 weeks.
- One daily injection, no cycling: The approved schedule is once daily under the skin of the abdomen. Skipped days, on-off cycles and doses outside the label were not tested in the approval trials.
- Not a weight-loss drug: The label states tesamorelin is not indicated for weight loss and had a weight-neutral effect in the trials.
- Results fade when it stops: In the trials, belly fat that had been reduced came back within 26 weeks of switching to placebo.
Tesamorelin Dosage Chart by Formulation
| Product | Vial strength | Labeled dose | How often | Mixed vial use |
|---|---|---|---|---|
| EGRIFTA WR (approved 2025) | 11.6 mg per vial | 1.28 mg (0.16 mL of the mixed solution) | Once daily under the skin of the abdomen | One vial covers 7 daily doses; discard 7 days after mixing |
| EGRIFTA SV | 2 mg per vial | 1.4 mg (0.35 mL of the mixed solution) | Once daily under the skin of the abdomen | Single dose; use right after mixing and throw away the rest |
| Original EGRIFTA (discontinued; used in pivotal trials) | 1 mg per vial | 2 mg | Once daily under the skin | Two vials per dose |
Sources: EGRIFTA WR prescribing information (revised 3/2025) and EGRIFTA SV prescribing information (revised 2/2024). This chart summarizes FDA labeling for a prescription drug. The original EGRIFTA 2 mg dose is historical trial context, not a current EGRIFTA WR or SV prescribing instruction. This chart is not a substitute for a prescriber's instructions.
What is tesamorelin?
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal from the brain that tells the pituitary gland to release growth hormone. It contains the full 44-amino-acid sequence of human GHRH with a small chemical group added to make it more stable. Tesamorelin raises the body's own growth hormone output, which in turn raises IGF-1. It is made by Theratechnologies and sold in the United States under the EGRIFTA brand names. For the approval history and current status, see our tesamorelin FDA approval status guide.
Why do EGRIFTA WR, SV and the original EGRIFTA have different doses?
The formulations differ, so the same blood level is reached with different milligram amounts. FDA labeling states that the 1.28 mg dose of EGRIFTA WR and the 1.4 mg dose of EGRIFTA SV each produce systemic exposure similar to the 2 mg dose of the original 1 mg-per-vial EGRIFTA. That bioavailability match is how FDA approved the newer versions without repeating the full efficacy trials.
The practical point is that the number on the box is not the dose, and one product cannot be swapped for another at the same milligram amount. The WR label states plainly that EGRIFTA WR and EGRIFTA SV are not substitutable, because the dose, the number of vials per dose, the mixing instructions and storage all differ. Theratechnologies announced in September 2025 that EGRIFTA WR would gradually replace EGRIFTA SV, with SV remaining available during a transition period (Theratechnologies announcement).
What tesamorelin dose did the clinical trials use?
The two trials behind the approval used 2 mg of the original EGRIFTA formulation once daily. They randomized 816 adults with HIV, lipodystrophy and excess abdominal fat, about 85% of them men, to tesamorelin or placebo for 26 weeks. Belly-fat volume measured by CT scan (visceral adipose tissue) fell by 18% in Study 1 and 14% in Study 2 with tesamorelin, compared with a 2% rise and a 2% fall with placebo. Body weight did not change meaningfully. Average IGF-1 rose by about 107 to 108 ng/mL with tesamorelin.
The label summarizes the main results in these terms:
| Measure at week 26 | Study 1 (tesamorelin vs placebo) | Study 2 (tesamorelin vs placebo) |
|---|---|---|
| Change in visceral fat | -18% vs +2% | -14% vs -2% |
| Change in waist size | -3 cm vs -1 cm | -2 cm vs -1 cm |
| Change in body weight | -0.4 kg vs 0.0 kg | +0.5 kg vs +0.3 kg |
For how those changes unfolded week by week, see how long tesamorelin takes to work.
Have other studies used different tesamorelin doses?
Yes, a few research trials outside the approved use have tested tesamorelin, mostly at the same 2 mg daily amount. These were studies, not approved uses:
- Fatty liver in people with HIV: 61 adults were enrolled, with 60 randomised to tesamorelin 2 mg daily or placebo for 12 months, followed by a 6-month open-label phase in which participants received tesamorelin (Stanley et al., Lancet HIV, 2019).
- Abdominal obesity with low growth hormone output: 2 mg once daily for 12 months in 60 adults with abdominal obesity and reduced growth hormone secretion (Makimura et al., Journal of Clinical Endocrinology and Metabolism, 2012).
- Older adults with and without mild cognitive impairment: 1 mg once daily, self-injected 30 minutes before bedtime for 20 weeks; a brain-imaging substudy reported results for 30 participants (Friedman et al., JAMA Neurology, 2013).
These studies show what researchers tested in specific groups under medical supervision. They do not establish a dose for weight loss, muscle gain, anti-aging or any other use, and none of these uses is FDA-approved.
Is tesamorelin approved for weight loss or bodybuilding?
No. The label lists three limitations of use: tesamorelin is not indicated for weight loss management because it has a weight-neutral effect, its long-term cardiovascular safety has not been established, and there are no data showing it improves adherence to HIV medicines. There is no FDA-approved tesamorelin dose for fat loss in people without HIV, for muscle building or for performance. Tesamorelin is also prohibited in tested sport as a growth hormone-releasing factor under the World Anti-Doping Agency's S2 category (WADA Prohibited List).
What happens when you stop taking tesamorelin?
The fat reduction does not last after stopping. In the trial extensions, people who had taken tesamorelin for 26 weeks were randomly switched either to continue it or to placebo. Participants who continued tesamorelin maintained their visceral-fat reductions through week 52, with changes of 0% in Study 1 and -5% in Study 2 between weeks 26 and 52. Those switched to placebo regained visceral fat, by 22% in Study 1 and 16% in Study 2 over the next 26 weeks, largely reversing the earlier reduction. The label adds that treatment should be weighed carefully in people who have not had a reduction in visceral fat.
What are the side effects of tesamorelin?
The most common side effects in the trials were joint pain, injection-site redness and itching, pain in the arms or legs, swelling in the legs or ankles, and muscle aches. The adverse-reaction rates below come from clinical trials of the original 1 mg-per-vial EGRIFTA formulation, which support the efficacy and safety information in the newer product labels. Over the first 26 weeks, injection-site reactions occurred in 25% of people on tesamorelin and 14% on placebo. Hypersensitivity reactions such as rash, hives, itching and flushing occurred in 4%.
The label also includes these warnings:
- Higher IGF-1: 47% of people taking tesamorelin for 26 weeks had IGF-1 levels more than 2 standard deviations above normal. The effects of long-term high IGF-1 are unknown, so the label calls for IGF-1 monitoring.
- Blood sugar: Tesamorelin can cause glucose intolerance. HbA1c reached 6.5% or higher in 5% of people on tesamorelin versus 1% on placebo, and glucose should be checked before and during treatment.
- Fluid retention: Swelling, joint pain and carpal tunnel syndrome can occur and usually resolve when treatment stops.
- Malignancy: Active malignancy is a contraindication. For patients with a history of cancer, the label says the malignancy must be inactive and treatment completed before tesamorelin is considered; treatment should stop if malignancy recurs.
The label lists these contraindications: pregnancy, active malignancy, known allergy to tesamorelin or its ingredients, and disrupted pituitary function from pituitary surgery, a pituitary tumor, head radiation or head injury. Seek emergency care right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling of the face, lips or throat, widespread hives, or fainting (MedlinePlus: anaphylaxis). Side effects can be reported to FDA MedWatch.
How long does tesamorelin last in the body?
Not long. After a single 1.28 mg injection of EGRIFTA WR in healthy adults, tesamorelin reached its peak in the blood after about 9 minutes and had a half-life of about 11 minutes. Its effects on growth hormone and IGF-1 last longer than the drug itself, which is part of why the trials used a once-daily schedule.
Is a research-vial tesamorelin dose the same as EGRIFTA?
No. Tesamorelin sold online as a research peptide, usually in vials labeled 2 mg, 5 mg or 10 mg, is not EGRIFTA. It is not FDA-approved for human use, its identity, purity and potency have not been checked by FDA, and the label doses above were established only for the EGRIFTA products with their own ingredients and mixing instructions. The milligram amount on a research vial is a claimed product quantity, not a dose. Our tesamorelin dosage calculator models research-vial concentration and volume arithmetic only. It does not establish a safe or effective human dose, confirm vial contents, or convert an EGRIFTA prescription into a research-vial dose. For prescription and research-vial pricing, see how much tesamorelin costs.
Frequently asked questions
How much tesamorelin should I take per day?
The FDA-approved dose is 1.28 mg once daily for EGRIFTA WR or 1.4 mg once daily for EGRIFTA SV, for adults with HIV and lipodystrophy who have excess abdominal fat. Whether tesamorelin is appropriate, and at what dose, is a decision for a prescriber.
Is 2 mg of tesamorelin the same as 1.28 mg of EGRIFTA WR?
No, not as an interchangeable dose. FDA labeling reports similar systemic exposure from 1.28 mg of EGRIFTA WR and 2 mg of the original EGRIFTA formulation used in the pivotal trials. This comparison does not mean that 2 mg from another formulation or a research vial is equivalent to 1.28 mg of EGRIFTA WR.
Can tesamorelin be taken every other day or in cycles?
The approval trials used continuous once-daily dosing. Every-other-day schedules and on-off cycles have not been tested in those trials, and the trials showed that the fat reduction reversed after stopping.
Can women take tesamorelin?
The approved use applies to adults of either sex, though about 85% of people in the pivotal trials were men. Tesamorelin is contraindicated in pregnancy, and the label advises mothers with HIV not to breastfeed.
About this article: PeptideStack is an affiliate-supported research publisher. The Peptide Partners card on this page is a paid referral offer and is not medical guidance. This article summarises FDA labeling and published tesamorelin research; it does not recommend purchasing or using tesamorelin. Dosing of a prescription drug should come from a licensed healthcare professional.
You Might Also Like

Tesamorelin FDA Approval Status 2026
Tesamorelin (Egrifta) FDA approval dates, Phase 1 and Phase 3 trial dates, FDA label indications, latest research 2025-2026, and tesamorelin availability 2026.

How Long Does Tesamorelin Take to Work? Timeline
How long — and how fast — tesamorelin takes to work based on the longest clinical trial duration and published timeline for IGF-1 and visceral fat changes.

How Much Does Tesamorelin Cost? 2026 Pricing
How much does tesamorelin cost? Compare research vial pricing, Peptide Partners pricing, and prescription Egrifta monthly cost.

